Any side effects from Infini-B?

STOP LISTENING TO RANDOS ONLINE! Nobody should EVER link Wikipedia as a primary source. Anyone can edit those articles and misinterpret data. You have to read the actual studies. Wikipedia is fine to set you off in a direction to find information, but it should never be used as the data itself. The citations from that claim is from 1985. They have done more recent research showing P5P does NOT have that effect.

https://pubmed.ncbi.nlm.nih.gov/28716455/

In the present study, the neurotoxicity of the different forms of vitamin B6 is tested on SHSY5Y and CaCo-2 cells. Cells were exposed to pyridoxine, pyridoxamine, pyridoxal, pyridoxal-5-phosphate or pyridoxamine-5-phosphate for 24h, after which cell viability was measured using the MTT assay. The expression of Bax and caspase-8 was tested after the 24h exposure. The effect of the vitamers on two pyridoxal-5-phosphate dependent enzymes was also tested. Pyridoxine induced cell death in a concentration-dependent way in SHSY5Y cells. The other vitamers did not affect cell viability. Pyridoxine significantly increased the expression of Bax and caspase-8. Moreover, both pyridoxal-5-phosphate dependent enzymes were inhibited by pyridoxine. In conclusion, the present study indicates that the neuropathy observed after taking a relatively high dose of vitamin B6 supplements is due to pyridoxine. The inactive form pyridoxine competitively inhibits the active pyridoxal-5'-phosphate. Consequently, symptoms of vitamin B6 supplementation are similar to those of vitamin B6 deficiency.

They even go into the mechanism. High levels of pyridoxine can inhibit the P5P enzymes, causing a drop in B6 function. So taking too much pyridoxine fucks up the body's ability to create the active P5P form. Supplementing P5P itself does NOT have that effect. Even if you read the full paper from 1985, it doesn't say what the Wikipedia citation claims.

http://62.182.86.140/scimag/7026711/Neurotoxicity%20of%20pyridoxine%20analogs%20is%20related%20to%20coenzyme%20structure%20%28Molecular%20and%20Chemical%20Neuropathology%20%28Neurochemical%20Pathology%29%2C%20vol.%203%2C%20issue%203%29%20%281985%29.pdf

The observation that the phosphorylated derivative was not toxic also suggested that it was not a physical effect of the molecule on the cell membrane that produced cell injury. Several mechanisms might account for the correlation between ability to serve as active coenzyme and toxic effect. In high concentrations, pyridoxine compounds combine together or with a second unidentified intracellular constituent to inhibit the pyridoxal. This might involve the formation of a hydrazone or other molecule similar to that produced with isoniazid (McCormick and Snell, 1959; McCormick et al., 1960; McCormick and Snell, 1961). These derivatives inhibit pyridoxal kinase (ATP:pyridoxal 5-phosphotransferase, EC 2.7.1.35) that catalyzes the production of the phosphorylated coenzymes from pyridoxine, pyridoxal, or pyridoxamine. The nonphosphorylated compounds are inactive as coenzymes and presumably binding to pyridoxal phosphate-dependent enzymes is low. However, if the concentration is high enough, nonphosphorylated derivatives may bind competitively at the coenzyme site and block active coenzyme binding (Rudman and Williams, 1983). There is evidence that coenzyme attachment to the apoenzyme involves binding at two different sites on the molecule (Shive and Lansford, 1980). In massive doses, two coen- zyme molecules might become bound to the active site, one at each of the usual binding sites, rendering the enzyme inactive. At least one enzyme, pyridoxal kinase, is inhibited by excessive amounts of pyridoxal. However, in the latter case pyridoxal is the substrate rather than the coenzyme. The favored hypothesis is that one specific enzyme system is inhibited by excess pyridoxine or its analogs. If this were pyridoxal kinase one might expect inhibition of many pyridoxal phosphate-dependent enzyme systems. However, the animals and the humans who were studied extensively (Schaumburg et al., 1983; Windebank et al., in press) did not show any systemic ill effects. This suggests that either there is an enzyme system (that might be a neuron-specific pyridoxal kinase) restricted to neurons in general or to DRG neurons in particular. The former possibility might be manifested only at the DRG level because increasing blood levels of pyridoxine did not increase the levels in the central nervous system (Spector, 1978a,b; Bender and Totoe, 1984), because of the presence of an apparent BBB and a saturable uptake mechanism for these compounds (Spector, 1978a,b). However, as discussed above, the BBB is less competent at the DRG and toxin concentrations are potentially much higher than at other places in the peripheral or central nervous system.

So even in the 1985 paper they showed it was only an issue with nonphosphorylated B6 derivatives. They even postulated what was later proved to be true, that it was a competitive inhibition of enzyme inhibition by nonphosphorylated compounds. This does NOT apply to the phosphorylated P5P form. There have been ZERO documented cases of B6 toxicity from P5P. If your read the papers, it's actually a REDUCTION in P5P from too much pyridoxine inhibiting the enzyme used to convert B6 to its active P5P form. This is why toxicity from too much pyridoxine acts more like a P5P deficiency, because that's what it really does. It lowers the active P5P form by competitively binding and inhibiting the enzyme responsible for making P5P.